Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors
- 5 May 2005
- journal article
- case report
- Published by Wiley in Haemophilia
- Vol. 11 (3), 203-207
- https://doi.org/10.1111/j.1365-2516.2005.01096.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99Journal of Thrombosis and Haemostasis, 2004
- Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitorsHaemophilia, 2004
- Long‐term FEIBA prophylaxis does not prevent progression of existing joint diseaseHaemophilia, 2003
- Inhibitors: resolving diagnostic and therapeutic dilemmasHaemophilia, 2002
- Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse eventsHaemophilia, 2002
- Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic proceduresHaemophilia, 2001
- Effective Prophylaxis with Daily Recombinant Factor VIIa (rFVIIa-Novoseven) in a Child with High Titre Inhibitors and a Target JointThrombosis and Haemostasis, 2001
- Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitorsHaemophilia, 1999
- Haemophilia prophylaxis in young patients–a long‐term follow‐upJournal of Internal Medicine, 1997